Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A rare case of primary testicular follicular lymphoma in a pediatric patient.
J Hematop
January 2025
Mayo Clinic, Rochester, MN, USA.
Testicular follicular lymphoma (TFL) is an exceedingly rare lymphoma that typically occurs in young male patients and is now recognized as a distinct diagnostic entity in the International Consensus Classification. TFL shows some clinicopathologic and genetic overlap with pediatric-type follicular lymphoma (PTFL). We report a case of TFL occurring in an otherwise healthy 4-year-old boy who presented with painless scrotal swelling.
View Article and Find Full Text PDFTime trends of cancer incidence in young adults (20-49 years) in Italy. A population - based study, 2008-2017.
Tumori
November 2024
Agenzia di Tutela della Salute della Montagna Cancer Registry, Sondrio.
Article Synopsis
- The study evaluates cancer incidence trends from 2008-2017 in Italy among individuals aged 20-49, utilizing data from 20 cancer registries that cover about one-third of the population.
- Results show that cancer rates were nearly double for women compared to men, particularly due to breast and thyroid cancers, with significant variations in incidence trends across different cancer types.
- The findings indicate no consistent increase for early-onset cancers in Italy, with rising rates for some cancers offset by declines in others, underscoring the need for preventive measures and careful screening strategies.
'Misdiagnosis of diffuse large B-cell lymphoma in the maxillary sinus as a dental abscess'.
Ann Med Surg (Lond)
November 2024
Damascus University, Faculty of Dentistry, Damascus.
Introduction: Diffuse large B-cell Lymphoma (DLBCL) is a heterogeneous group of malignant tumors with diverse prognoses, histological appearances, and clinical symptoms. While it commonly affects lymphoid tissues, its occurrence in the nasal cavity and paranasal sinuses is rare and poses significant diagnostic challenges.
Case Presentation: The authors present a case of a 53-year-old man with a history of testicular non-Hodgkin lymphoma treated 5 months prior.
Prediction model of male reproductive function damage caused by CHOP chemotherapy regimen for non-Hodgkin's lymphoma.
BMC Cancer
November 2024
Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an City, Shanxi Province, 710049, China.
Objective: The CHOP combined chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is commonly used to treat non-Hodgkin Lymphoma (NHL). While these drugs are effective for cancer treatment, they may have side effects on the reproductive system that are poorly studied. This study used a mouse model to investigate the mechanisms of reproductive function impairment induced by the CHOP regimen and developed a predictive model for assessing reproductive damage with a non-invasive procedure.
View Article and Find Full Text PDF[Different Prophylaxis Strategies for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
October 2024
Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, Fujian Province, China.
Article Synopsis
- The study aimed to compare the effects of high-dose methotrexate (HD-MTX) and lenalidomide for preventing central nervous system (CNS) relapses in patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk for CNS recurrence.
- A retrospective analysis included 200 DLBCL patients, assessing CNS relapse-free survival (CRFS), progression-free survival (PFS), and overall survival (OS) rates among those treated with either HD-MTX or lenalidomide, with no significant survival differences found overall.
- Subgroup analysis revealed that while the CRFS rates were similar for high-risk patients in both groups, the lenalidom
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!